Neal Shore, MD, FACS

Dr Neal Shore shares how he would have treated the patient with metastatic prostate cancer from the presented case.

An overview of safety and efficacy data from the phase 3 PROfound trial evaluating the PARP inhibitor olaparib.

Neal Shore, MD, explains the available first-line treatment options for chemotherapy-naive, metastatic castration-resistant prostate cancer (mCRPC).

A focused discussion on the significance of mutations in homologous recombination repair (HRR)-related genes in prostate cancer.

An expert urologist highlights the vital importance of genetic testing in cases of prostate cancer.

Dr Neal Shore gives his first impressions of a patient case and gauges the risk of progression.

Neal Shore, MD, presents the case of a 64-year-old man with metastatic prostate cancer and a BRCA2 mutation.

Dr Steven Finkelstein explains a clinical example of a 65-year-old patient with a history of robotic radical prostatectomy for Gleason 9 adenocarcinoma.

Dr Lawrence Saperstein describes the patient profile of a 78-year-old man with a history of intensity-modulated radiation therapy for adenocarcinoma.

Key opinion leaders review the CONDOR clinical trial studying PSMA PET scans for prostate cancer imaging.

Michael Gorin, MD, presents a clinical example of a 60-year-old patient with recurrent prostate cancer.

A panel of experts review whether bone scans still have a place in prostate cancer imaging.

Steven Finkelstein, MD, DABR, FACRO, presents a high-risk prostate cancer patient profile for a 74-year-old man with a history of chronic prostatitis.

Lawrence Saperstein, MD, reviews the patient profile of a 65-year-old man with high-risk prostate cancer.

A look at how PSMA PET imaging fits into the monitoring of a patient with prostate cancer.

A radiation oncologist explains how to discuss the interpretation of prostate cancer imaging with patients in deciding on a treatment plan.

Dr Lawrence Saperstein describes the importance of coronal images and visual analysis in making a thoughtful treatment plan for prostate cancer.

Authors from the OSPREY clinical trial highlight the key take-home messages from the trial outcomes.

Key opinion leaders review the OSPREY clinical trial studying PSMA PET scans for prostate cancer imaging.

Doctors present the patient profile of a 66-year-old man with high-risk localized prostate cancer.

Michael Gorin, MD, describes his experiences with prostate cancer imaging both in academia and community-based practices.

An explanation of the importance of clinical providers following a multidisciplinary approach for prostate cancer management.

Experts review ongoing clinical trials in PSMA PET technology.

The panel explains the science behind PSMA PET scans and reviews the different positron-emitters used in the scans.

A background on the available options and recent advances in prostate cancer imaging.

Bobby Liaw, MD; Vivek K. Narayan, MD, MS; Ashley E. Ross, MD, PhD; and Neal Shore, MD, FACS, provide closing thoughts and advice for the optimal management of advanced prostate cancer.

Experts in prostate cancer review the role of PSMA PET imaging in advanced prostate cancer and its impact on disease management.

Bobby Liaw, MD, and Vivek K. Narayan, MD, MS, share clinical pearls for the management of adverse events from ARI-directed therapy in advanced prostate cancer.

Ashley E. Ross, MD, PhD, comments on the clinical significance of PSA response in patients with nmCRPC.

Vivek K. Narayan, MD, MS, reviews data from the SPARTAN trial in nmCRPC and discusses the importance of assessing health-related quality of life.